US investment restrictions come after years of declining cross-border financing, even as Chinese drug assets attract growing international demand.
On October 22, the US Treasury Department proposed new restrictions on American investment in Chinese biotechnology. The proposal could prohibit covered investments in companies engaged in a wide range of pharmaceutical activities, including those involving small molecules, antibodies, vaccines, and cell and gene therapies.
The timing matters. American investors had already reduced their exposure to China, while Chinese biotech companies were increasingly licensing their drug candidates to global pharmaceutical companies.
COINS may accelerate this shift, but its impact will depend on how much Chinese biotech still relies on American capital and whether alternative financing can replace it.
American capital was leaving before COINS
American investment in Chinese biotechnology was once substantial.
A 2024 study by the French Institute of International Relations (Ifri), using Crunchbase data, identified 341 American investment participations in Chinese biotechnology between 2019 and 2023, compared with 324 in artificial intelligence. Biotechnology was an important destination for American investors, not a peripheral sector. [1]
That investment environment changed sharply after 2021.
According to the Global Private Capital Association, fundraising by China-focused, US dollar-denominated venture funds fell from $17.5 billion in 2022 to approximately $1.4 billion in 2024. These figures cover all industries and are not a measure of American investment alone. They nevertheless show how quickly an important source of international venture funding contracted. [2]
Chinese biopharma financing followed a similar pattern. PharmaDJ reported that private financing declined from $8.1 billion in 2022 to $3.3 billion in 2024, a 59% decrease. Its 2024 report attributed $1.2 billion, or 36% of the financing it tracked, to US funds. However, the publicly available data do not provide a complete breakdown of the amounts contributed by individual American investors. [3]
Oliver Wyman reported a similar decline in international participation, estimating that overseas investors' share of Chinese life sciences venture financing fell from 23% in 2020 to 10% in 2024. [4]
These figures use different definitions of foreign capital, but they point to the same broad trend. Chinese biotech had already become less reliant on international venture financing before Treasury proposed the new restrictions.
The decline also had several causes, including weaker IPO markets, changing investor appetite, geopolitical tensions, and China's broader economic slowdown. It cannot be attributed to COINS, which was enacted in December 2025 and whose biotechnology restrictions have not yet taken effect.
Capital is returning, but where is it going?
Chinese biopharma financing began recovering in 2025. PharmaDJ recorded $4.58 billion in private financing, up 39% from 2024. Its first-half 2026 report showed $4.64 billion, although the treatment of some large international financings requires caution. [5,6]
Several transactions illustrate how international capital continues to participate in Chinese-origin drug development.
Earendil Labs announced $787 million raised across financing rounds in March 2026, backed by investors including Dimension Capital, DST Global, Sanofi, and a biotechnology fund established by Hillhouse and Pfizer. Earendil operates through an overseas entity associated with China's Helixon. PharmaDJ included $787 million in its first-half 2026 financing analysis, but Earendil's announcement did not establish that the entire amount was raised in one new round. [6,7]
Angitia Biopharmaceuticals, with operations in California and Guangzhou, raised $130 million in February 2026. The Series D was co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners. Accro Bioscience, operating in New York and Suzhou, raised $50 million in May, led by OrbiMed with participation from TCGX and other investors. [8,9]
International investors also continue to finance companies based directly in China. Shanghai-based Vivacta Biotechnology announced more than $50 million across Series A and A+ financings in April 2026, with participation from Decheng Capital, OrbiMed, and several Chinese investment firms. [10]
These transactions show continued interest from specialized healthcare investors. They also reveal an important distinction that aggregate financing statistics often miss.
A company may originate from Chinese research, operate laboratories in China, and raise money through an international corporate structure. Another may remain incorporated in China while attracting overseas investors.
For investment analysis, these are not necessarily equivalent transactions.
Under the proposed COINS rules, the legal entity receiving investment, its ownership and control, and its relationships with Chinese entities could all affect whether a transaction is permitted. Simply registering a company outside China does not guarantee an exemption.
Drug assets are attracting capital that their developers may struggle to raise
The contrast between private financing and pharmaceutical licensing is increasingly important.
According to PharmaDJ, Chinese biotech companies completed 127 out-licensing agreements in 2025, up from 70 in 2024. Disclosed upfront commitments increased from approximately $4.2 billion to $8 billion.
However, the growth was concentrated. Twenty major transactions accounted for approximately three-quarters of the 2025 upfront total. In the first half of 2026, 16 large transactions generated $5.32 billion, or 88%, of reported out-licensing upfront commitments. [5,6]
This suggests strong international demand for selected Chinese drug candidates, rather than a broad improvement in financing conditions across the industry.
The difference matters because venture financing and licensing serve different purposes.
Venture capital funds early research, platform development, and clinical trials before a drug's commercial potential has been established. Licensing allows pharmaceutical companies to select assets based on their scientific and clinical evidence, often leaving part of the development risk with the original company.
The available data do not show that Chinese developers are systematically licensing earlier because of financing pressure. In fact, PharmaDJ reported that Phase II and III assets attracted the largest aggregate upfront payments in 2025, compared with preclinical and Phase I assets in 2024. [5]
Strong demand for established Chinese drug assets does not necessarily mean sufficient capital is available to develop the next generation.
The financing challenge may therefore become more pronounced among smaller companies and early-stage programs than among developers with attractive clinical assets.
What COINS could change
The proposed regulations would prohibit certain US equity investments and joint ventures involving covered biotechnology activities. Conventional cash-based pharmaceutical licensing would generally remain outside the defined investment transactions, although individual agreements would still require legal assessment. The final rules have not been issued, and Treasury is accepting comments until December 7, 2026. [11]
The distinction between investing in a company and licensing its drug candidates could become more important.
International investors may increasingly finance overseas development companies holding licensed rights to Chinese-origin assets, rather than taking equity directly in Chinese developers. Such NewCo structures are already gaining traction. BioCentury, as reported by PharmaDJ, identified at least 13 Western NewCos established with Asian-origin assets in the first half of 2026, nine of which involved Chinese-origin assets. [6]
These structures are not automatically exempt from COINS. Ownership, control, and the economic terms of the arrangement remain relevant.
There is also evidence that American specialist investors have not abandoned the region. On October 15, just one week before Treasury's proposal, OrbiMed announced more than $1 billion raised for its sixth Asia-focused fund, explicitly citing China's emergence as a biotechnology powerhouse among the sector's investment opportunities. [12]
The fund is not dedicated exclusively to China. Nevertheless, its timing highlights the tension between commercial interest in Chinese innovation and increasing restrictions on direct investment.
The outlook for 2027–2029
The immediate effect of COINS may be concentrated in new private equity financing rather than pharmaceutical licensing.
If the broad biotechnology provisions remain in the final regulations, covered Chinese developers could face reduced access to American venture capital. The impact would depend on whether domestic Chinese funds and other international investors can provide replacement financing.
In 2027, the first signs should appear in financing rounds: fewer American investors in covered transactions, changes in fund participation, and greater scrutiny of international corporate structures.
By 2028–2029, the consequences could become more apparent in drug development. Companies unable to replace lost financing may delay clinical programs, seek partnerships sooner, or license assets with less supporting evidence. Companies with stronger clinical data and established international operations may be less affected.
These are forecasts, not established outcomes. They could be weakened by a narrower final rule, stronger domestic financing, or increased investment from non-US sources.
The most useful indicators will be American participation in early-stage financing, the clinical stage of newly licensed assets, and the share of future commercial rights retained by Chinese developers.
COINS is unlikely to affect every Chinese biotech equally. Its impact will depend on the type of capital companies need and the alternatives available to them.
The key question is not whether Chinese medicines will continue reaching global markets. It is whether Chinese developers can secure enough capital to bring their innovations to the stage where they can negotiate the value those medicines deserve.
References
[1] Velliet M. Funding a Rival: When the United States and Europe Invest in Chinese Tech. French Institute of International Relations, July 2024.
[2] Global Private Capital Association. 2025 Trends in Global Tech. March 2025, p. 29.
[3] PharmaDJ. China Biopharma Tracker 2024. January 13, 2025.
[4] Oliver Wyman. China: A Hotspot for Biopharma Innovation. May 2026.
[5] PharmaDJ. China Biopharma Tracker 2025. December 31, 2025.
[6] PharmaDJ. Financing Jumps 269% in H1 2026, Surpasses Full-Year 2025 Total. July 7, 2026.
[7] Earendil Labs. Earendil Labs Announces $787 Million in Financing. March 20, 2026.
[8] Angitia Biopharmaceuticals. Announcement of $130 Million Series D Financing. February 5, 2026.
[9] Accro Bioscience. Announcement of $50 Million Series C Financing. May 18, 2026.
[10] Vivacta Biotechnology. Vivacta Bio Closed Series A and Series A+ Financing of Over US$50 Million. April 29, 2026.
[11] US Department of the Treasury. Proposed Regulations to Implement the COINS Act. October 22, 2026.
[12] OrbiMed. OrbiMed Raises $3 Billion Across Global and Asia Private Equity Funds. October 15, 2026